Corvidane has taken a truly innovative approach to treat Cardiovascular and Metabolic diseases.
Corvidane’s drug Corvida™ is a patented composition of fatty acids that were selected for their molecular structures and extraordinary chemical properties.
First conceived of by Chemical Engineers, Corvida™’s lipid-based mechanisms of action target the root causes of Atherosclerosis NonAlcoholic SteatoHepatitis (NASH).
Corvidane’s approach to drug development has addressed several traditional “points-of-failure” thus de-risking further development and reducing time-to-approval.
Corvidane’s Management and Advisory Teams have the traditional drug experience and fatty acid therapeutics expertise to make Corvida™ a clinical and commercial success.
We are raising $9.6M USD to develop Corvida™ into two Phase II-ready assets for license or acquisition.